Although it is treatable, it’s not considered to be curable. In the early stages, CLL often doesn't require treatment immediately, as studies have shown that early treatment doesn’t increase ...

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed treatment for a patient with chronic ...

This represents a challenging duty for physicians treating CLL patients in the day-to-day practice. What is clear is that any method of measuring fitness in CLL patients must be simple and easy to ...

Panelists discuss how challenges in implementing emerging Bruton tyrosine kinase inhibitor (BTKi) regimens for ...

Cardiovascular management strategies are essential to individuals with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) undergoing active treatment, due to the high rate of atrial ...

Treatment for CLL continues to change. Doctors are using newer targeted cancer drugs. This means a stem cell transplant is now a less common treatment for CLL. You have a transplant using donor cells ...

The study noted that people with skin cancer and CLL were also more likely to develop other cancers. Treating CLL with a tyrosine kinase inhibitor (TKI) drug called ibrutinib seemed to reduce the ...

Although everyone’s CLL journey is different, there tend to be shared milestones that can give patients a sense of progress, as well as resilience, when navigating treatment options. Here’s what ...

During a Case-Based Roundtable® event, Catherine Coombs, MD, discussed the BRUIN trial and recent NCCN updates on chronic ...

Where you start on your CLL journey matters. Biomarker testing changed everything for Nathan, enabling him to find the right treatment for his needs. Watch his story to discover why biomarker testing ...

1,3 The campaign is anchored by a real patient’s journey with CLL and how his experience with testing before treatment helped him select a treatment that offered a potentially better outcome.

SAN DIEGO -- Pirtobrutinib (Jaypirca) delayed disease progression versus other available options in patients with chronic lymphocytic leukemia (CLL) who had previously received a covalent Bruton's ...